Opportunities for Small Molecules in Cancer Immunotherapy

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.

Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212

The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells

Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395

Successes and challenges in clinical gene therapy

Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 209

Drug combination therapy for emerging viral diseases

Shyr, Z. A., Cheng, Y., Lo, D. C., & Zheng, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.008 · Cited by 191

Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors

Mei, K., Liao, Y., Jiang, J., Chiang, M., Khazaieli, M., Liu, X., Wang, X., Liu, Q., Chang, C. H., Zhang, X., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c05194 · Cited by 162

Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations

Gilad, Y., Gellerman, G., Lonard, D. M., & O’Malley, B. W. (2021) · Cancers · doi:10.3390/cancers13040669 · Cited by 146

Small molecule-based immunomodulators for cancer therapy

Wu, Y., Yang, Z., Cheng, K., Bi, H., & Chen, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.007 · Cited by 114

Epigenetic state determines the in vivo efficacy of STING agonist therapy

Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94

Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy

Chen, Y., Zhi, S., Ou, J., Gao, J., Zheng, L., Huang, M., Du, S., Shi, L., Tu, Y., & Cheng, K. (2023) · ACS Nano · doi:10.1021/acsnano.3c02724 · Cited by 86

Maximizing response to intratumoral immunotherapy in mice by tuning local retention

Momin, N., Palmeri, J. R., Lutz, E. A., Jailkhani, N., Mak, H. H., Tabet, A., Chinn, M. M., Kang, B. H., Spanoudaki, V. C., Hynes, R. O., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27390-6 · Cited by 81

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 72

Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy

Choi, J., Park, B., Park, J. Y., Shin, D., Lee, S., Yoon, H. Y., Kim, K., Kim, S. H., Kim, Y., Yang, Y., et al. (2024) · Advanced Materials · doi:10.1002/adma.202405475 · Cited by 77

Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3

Chung, Y. M., Khan, P. P., Wang, H., Tsai, W.-B., Qiao, Y., Yu, B., Larrick, J. W., & Hu, M. C. ‐. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002772 · Cited by 67

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds

Vara, B., Levi, S. M., Achab, A., Candito, D. A., Fradera, X., Lesburg, C. A., Kawamura, S., Lacey, B. M., Lim, J., Methot, J. L., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00096 · Cited by 65

Design, Synthesis, and Evaluation of o -(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo

Ouyang, Y., Gao, J., Zhao, L., Lu, J., Zhong, H., Tang, H., Jin, S., Lü, Y., Li, Y., Guo, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00370 · Cited by 58

STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer

Shi, J., Liu, C., Luo, S., Cao, T., Lin, B., Zhou, M., Zhang, X., Wang, S., Zheng, T., & Li, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104384 · Cited by 52

Microfluidic technologies for immunotherapy studies on solid tumours

Paterson, K., Zanivan, S. R., Glasspool, R. M., Coffelt, S. B., & Zagnoni, M. (2021) · Lab on a Chip · doi:10.1039/d0lc01305f · Cited by 51

Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?

Tajaldini, M., Saeedi, M., Amiriani, T., Amiriani, A., Sedighi, S., Zadeh, F. M., Dehghan, M. H., Jahanshahi, M., Zanjan, M. G., Khalili, P., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175087 · Cited by 46

Multi-Organs-on-Chips for Testing Small-Molecule Drugs: Challenges and Perspectives

Çeçen, B., Karavasili, C., Nazir, M., Bhusal, A., Dogan, E., Shahriyari, F., Tamburacı, S., Büyüköz, M., Kozacı, L. D., & Miri, A. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101657 · Cited by 37

Self‐Degradable Nanogels Reshape Immunosuppressive Tumor Microenvironment via Drug Repurposing Strategy to Reactivate Cytotoxic CD8+ T Cells

Tian, H., Li, W., Wang, G., Tian, Y., Yan, J., Zhou, S., Yu, X., Li, B., & Dai, Y. (2023) · Advanced Science · doi:10.1002/advs.202301661 · Cited by 34

Hydrogels for Engineering the Immune System

Li, X., Shou, Y., & Tay, A. K. P. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000073 · Cited by 34

Discovery of Orally Bioavailable N-Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer

Li, X., Yang, S., Zhang, H., Liu, X., Gao, Y., Chen, Y., Liu, L., Wang, D., Liang, Z., Liu, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01444 · Cited by 32

Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment

Singh, S., Barik, D., Arukha, A. P., Prasad, S., Mohapatra, I., Singh, A. R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11102621 · Cited by 31

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

Darrigrand, R., Pierson, A., Rouillon, M., Renko, D. Z., Boulpicante, M., Bouyssié, D., Mouton‐Barbosa, E., Marcoux, J., Garcia, C., Ghosh, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01801-2 · Cited by 28

Transforming Cold Tumors into Hot Ones with a Metal–Organic Framework-Based Biomimetic Nanosystem for Enhanced Immunotherapy

Xu, M., Chang, Y., Zhu, G., Zhu, X., Song, X., & Li, J. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c21005 · Cited by 30

Localized delivery of immunotherapeutics: A rising trend in the field

Wang, J., Zhang, Y., Pi, J., Xing, D., & Wang, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.013 · Cited by 31

ROS-triggered nanoinducer based on dermatan sulfate enhances immunogenic cell death in melanoma

Zhang, Q., Li, S., Ren, J., He, X., Shi, H., Zhang, F., Li, H., & Tong, R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.026 · Cited by 29

Small-Molecule PROTACs for Cancer Immunotherapy

Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 30

Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Shi, H., Tang, H., Li, Y., Chen, D., Liu, T., Chen, Y., Wang, X., Chen, L., Wang, Y., Xie, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115064 · Cited by 27

The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches

Koumarianou, A. A., & Durán, J. (2021) · Cancers · doi:10.3390/cancers13030363 · Cited by 28

G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma

Lam, M. S. Y., Reales‐Calderón, J. A., Ow, J. R., Aw, J., Tan, D., Vijayakumar, R., Ceccarello, E., Tabaglio, T., Lim, Y. T., Chien, W. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36160-5 · Cited by 26

Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer

Wang, T., Wu, L., Wang, S., Shi, X., Liu, H., & Deng, W. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60451-0 · Cited by 25

Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines

Zhang, W., Zheng, X., Coghi, P. S., Chen, J.-H., Dong, B.-J., & Fan, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1438030 · Cited by 27

Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy

Han, C., Zhang, A., Liu, Z., Moore, C., & Fu, Y. (2020) · Oncogene · doi:10.1038/s41388-020-01575-7 · Cited by 22

Potential therapeutic uses of rexinoids

Leal, A. S., Reich, L. A., Moerland, J. A., Zhang, D., & Liby, K. T. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.01.004 · Cited by 26

Immunomodulatory drug discovery from herbal medicines: Insights from organ-specific activity and xenobiotic defenses

Shi, J., Weng, J., & Mitchison, T. J. (2021) · eLife · doi:10.7554/elife.73673 · Cited by 23

Small-molecule in cancer immunotherapy: Revolutionizing cancer treatment with transformative, game-changing breakthroughs

Chattopadhyay, S., Hazra, R., Mallick, A., Gayen, S., & Roy, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189170 · Cited by 23

Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma

Ou, J., Zheng, L., Chen, Y., Fu, Q., Tan, L., Liang, E. Y., Huang, L., Pan, Y., Ke, J., Chen, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01504 · Cited by 21

Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins

Dai, Z., Zhu, P.-F., Liu, H., Li, X., Zhu, Y.-Y., Liu, Y., Shi, X., Chen, W.-D., Liu, Y., Zhao, Y., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154335 · Cited by 20

Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes

Ahmad, M. S., Braoudaki, M., Patel, H., Ahmad, I., Shagufta, S., & Siddiqui, S. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254911 · Cited by 20

Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles

Fernandes, S., Cassani, M., Cavalieri, F., Forte, G., & Caruso, F. (2023) · Advanced Science · doi:10.1002/advs.202305769 · Cited by 20

Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase

Kozlova, A., Thabault, L., Liberelle, M., Klaessens, S., Prévost, J. R. C., Mathieu, C., Pilotte, L., Stroobant, V., den Eynde, B. J. V., & Frédérick, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00323 · Cited by 20

Immune organoid for cancer immunotherapy

Wang, X., Wang, W., & Sun, Z. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.031 · Cited by 21

Structures/cytotoxicity/selectivity relationship of natural steroidal saponins against GSCs and primary mechanism of tribulosaponin A

Dai, Z., Liu, H., Wang, B., Yang, D., Zhu, Y.-Y., Yan, H., Zhu, P.-F., Liu, Y., Chen, H. C., Zhao, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113068 · Cited by 19

Discovery of novel N-sulfonamide-tetrahydroisoquinolines as potent retinoic acid receptor-related orphan receptor γt agonists

Ma, X., Sun, N., Li, X., & Fu, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113585 · Cited by 19

Discovery of ICOS‐Targeted Small Molecules Using Pharmacophore‐Based Screening

Calvo‐Barreiro, L., Talagayev, V., Pach, S., Abdel‐Rahman, S. A., Wolber, G., & Gabr, M. T. (2023) · ChemMedChem · doi:10.1002/cmdc.202300305 · Cited by 19

Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors

Zhang, J., Li, Y., Tang, H., Zhou, Q., Tong, L., Ding, J., Xie, H., Xiong, B., & Liu, T. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106811 · Cited by 17

The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer

Leal, A. S., Moerland, J. A., Zhang, D., Carapellucci, S., Lockwood, B., Krieger-Burke, T., Aleiwi, B., Ellsworth, E. L., & Liby, K. T. (2021) · Cancers · doi:10.3390/cancers13195004 · Cited by 16

Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios

Verano, A. L., You, I., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Fischer, E. S., Wang, E. S., & Gray, N. S. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00439 · Cited by 16

Synergistic therapeutic strategies for cancer treatment based on nanophototherapy

Liu, S., Song, R., Li, X., & Zhou, F. (2021) · Nanophotonics · doi:10.1515/nanoph-2021-0407 · Cited by 16

Immunotherapies for locally aggressive cancers

Adams, S. C., Nambiar, A., Bressler, E. M., Raut, C. P., Colson, Y. L., Wong, W. W., & Grinstaff, M. W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115331 · Cited by 15

Bioengineering nanomaterials for tumor therapy and anti-metastasis

Cheng, J., Pan, Y., Zou, J., Zhang, M., Zhu, Y., Liu, Y., & Chen, X. S. (2024) · Progress in Materials Science · doi:10.1016/j.pmatsci.2024.101375 · Cited by 15

GALNT6 dual regulates innate immunity STING signaling and PD-L1 expression to promote immune evasion in pancreatic ductal adenocarcinoma

Chong, S., Liu, Y., Bian, Z., Hu, D., Guo, S., Dong, C., Zeng, J., Fan, S., & Chen, X. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111942 · Cited by 14

Maleimide functionalized polycaprolactone micelles for glutathione quenching and doxorubicin delivery

Babanyinah, G. K., Bhadran, A., Polara, H., Wang, H., Shah, T. V., Biewer, M. C., & Stefan, M. C. (2024) · Chemical Science · doi:10.1039/d4sc01625d · Cited by 14

Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents

Pla-López, A., Castillo, R., Cejudo-Marín, R., García‐Pedrero, O., Bakir, M., Falomir, E., & Cardá, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137049 · Cited by 14

Repurposing Ponatinib as a PD-L1 Inhibitor Revealed by Drug Repurposing Screening and Validation by In Vitro and In Vivo Experiments

Barnwal, A., Das, S., & Bhattacharyya, J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00214 · Cited by 13

Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan

Kakraba, S., Ayyadevara, S., Mainali, N., Balasubramaniam, M., Bowroju, S., Penthala, N. R., Atluri, R., Barger, S. W., Griffin, S. T., Crooks, P. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16101498 · Cited by 10

Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis

Zhang, H., Chen, Y., Jiang, X., Gu, Q., Yao, J., Wang, X., & Wu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1333124 · Cited by 13

Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma

Chacon, A. C., Melucci, A. D., Qin, S. S., & Prieto, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063228 · Cited by 12

Sulfobetaine methacrylate-coated reduced graphene oxide-IR780 hybrid nanosystems for effective cancer photothermal-photodynamic therapy

Melo, B. L., Lima‐Sousa, R., Alves, C. G., Correia, I. J., & de Melo‐Diogo, D. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123552 · Cited by 12

Novel classes of immunotherapy for breast cancer

Hernando‐Calvo, A., Cescon, D. W., & Bedard, P. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06405-2 · Cited by 11

Emerging immunological strategies: recent advances and future directions

Zhao, H., Luo, F., Xue, J., Li, S., & Xu, R. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0886-x · Cited by 12

Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells

Athanasiadis, P., Ravikumar, B., Elliott, R. J. R., Dawson, J. C., Carragher, N. O., Clemons, P. A., Johanssen, T., Ebner, D. V., & Aittokallio, T. A. (2023) · iScience · doi:10.1016/j.isci.2023.107209 · Cited by 10

Small molecule innate immune modulators in cancer therapy

Goswami, A., Goyal, S., Khurana, P., Singh, K., Deb, B., & Kulkarni, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395655 · Cited by 10

Stimulation and Suppression of the Innate Immune System through Nanotechnology

da Silva, M. C., Rocha, C. V., Bañobre‐López, M., & Gallo, J. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c03424 · Cited by 10

A self-delivery photodynamic sensitizer for enhanced DNA damage by PARP inhibition

Kong, R., Li, X., Huang, J., Zhou, X., Deng, F., Li, Y., Liu, L., Li, S., & Cheng, H. B. (2022) · Biomaterials Science · doi:10.1039/d2bm01320g · Cited by 9

Discovery of 3-(Fluoro-imidazolyl)pyridazine Derivatives as Potent STING Agonists with Antitumor Activity

Hou, H., Zhou, J., Sui, Q., Zhang, C., Su, Z., Cui, R., Shan, B., Xu, P., Chen, Z., Jiang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01873 · Cited by 8

Microsystem technologies for accelerating the discovery and translation of immunotherapies

Wang, Z., Liu, C. Y., Chen, K., Song, J. W., & Kelley, S. O. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01268-4 · Cited by 8

Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation

Swetha, K. L., Maravajjala, K. S., Li, S., Singh, M. S., & Roy, A. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01194-7 · Cited by 8

Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy

Liang, X., Zhao, H., Du, J., Li, X., Li, K., Zhao, Z., Bi, W., Zhang, X., Yu, D., Zhang, J., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115599 · Cited by 7

Neothalfine, a potent natural anti-tumor agent against metastatic colorectal cancer and its primary mechanism

Zhu, Y.-Y., Jin, Q., Chen, S.-S., Jin, D.-N., Wang, Z., He, Y., Chen, H. C., Zhao, Y., Zhao, L., Dai, Z., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115849 · Cited by 8

Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma

Feng, W., He, Z., Shi, L., Zhu, Z., & Ma, H. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10343-7 · Cited by 8

Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy

Hao, Y., Li, R., Pan, W., Tian, S., & Min, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00792 · Cited by 6

Prognostic significance of HSF2BP in lung adenocarcinoma

Huang, Z.-D., Liu, Z., Cheng, X., Han, Z., Li, J., Xia, T., Gao, Y., & Wei, L. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4935 · Cited by 7

Multiorgan-on-a-chip: an advanced platform for disease modeling, drug toxicity assessment, and therapeutic screening

Qiao, L., Chang, S., Zou, L., Zhang, F., Cui, C., & Huang, N. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2500076 · Cited by 6

Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies

Sunga, G. M., Hartgerink, J. D., Sikora, A. G., & Young, S. W. (2023) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2023.0090 · Cited by 6

Recent Trends in the Application of Materials for Cancer Therapy and Diagnosis

Bakhshandeh, B., Jahanafrooz, Z., Haghighi, D. M., Rahmani-Kukia, N., Abbasi, A., & Pourramezanali, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-2119-5_12 · Cited by 6

Advanced Therapeutic Approaches in Cancer Therapy

Sobti, R. C., Gosipatala, S. B., Reddy, P., Bisht, N., Kuril, S. R., Madhuri, K., Chand, G., Kaur, T., & Thakur, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-6263-1_79 · Cited by 5

Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for Cancer Immunotherapy

Lin, S., Xiang, N., Liu, W., Wu, D., Chen, Y., Xiong, T., Ge, J., Zhou, W. H., Tian, H., Zhang, K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01036 · Cited by 5

Molecular mechanisms of astragaloside-IV in hepatocellular carcinoma therapy: a systematic review

Gao, X. Y., Hao, W., Wang, Y., Wu, X., Zhu, F., & Zhang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14758-w · Cited by 5

Pyrimidyn‐Based Dynamin Inhibitors as Novel Cytotoxic Agents

Odell, L. R., Chau, N., Russell, C. C., Young, K. A., Gilbert, J., Robinson, P. J., Sakoff, J. A., & McCluskey, A. (2021) · ChemMedChem · doi:10.1002/cmdc.202100560 · Cited by 5

FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells.

Chung, Y. M., Tsai, W.-B., Khan, P. P., Ma, J., Berek, J. S., Larrick, J. W., & Hu, M. C. ‐. (2022) · PubMed Central · Cited by 5

Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein I through Molecular Dynamics with Probes and Virtual Screening

Andrade, L., Albuquerque, A., Santos-Costa, A. H., VASCONCELOS, D. B., Savino, W., Sartori, G., & da Silva, J. H. M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01122 · Cited by 5

Distepharinamide, a novel dimeric proaporphine alkaloid from Diploclisia glaucescens, inhibits the differentiation and proliferative expansion of CD4+Foxp3+ regulatory T cells

Chen, F., Geng, C., Chou, C., Zheng, J.-B., Yang, Y., Wang, Y., Li, T.-Z., Li, P., Chen, J., & Chen, X. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154482 · Cited by 5

PROTAC-powered synergistic tumor therapy

Wang, X., Zou, J., Tao, Y., Zhou, Z., Bian, C., Mao, Z., & Liu, Z. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.118678 · Cited by 4

RORγt agonist LYC-55716 potentiates IFN-α’s efficacy in hepatocellular carcinoma through enhancing cytotoxicity of Tc17 cells and infiltration of CD8+ T cells

Wang, H., Zhang, G., Zhao, C., Xue, Y., Zhu, D., & Chang, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116963 · Cited by 4

ISGylation prevents autophagic degradation of STING and promotes antitumor immunity in lung cancer

Cao, D., Bin, H., Fu, X., Liu, M., Niu, X., Zhai, H., & Huang, H. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08527-1 · Cited by 4

A novel pyroptosis-related indicator of immune infiltration features and prognosis in breast cancer

Wang, C., Zhang, L., Ren, L., Zhang, G., Wan, A., Xiong, S., Tian, H., Peng, Z., Zhao, T., Gao, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961500 · Cited by 4

Injectable polydopamine/curcumin dual-modified polylactic acid/polycaprolactone coaxial staple fibers for chronotropic treatment of oral squamous cell carcinoma

Chen, X., Sun, L., Ning, Y., Zhou, L., Guo, Y., Xu, R., & Wu, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139094 · Cited by 4

Challenges and Future Opportunities of Nanomedicine in Cancer Therapy

Narayan, S. (2021) · Springer eBooks · doi:10.1007/978-981-15-7564-8_10 · Cited by 4

Exploring Thiazolopyridine AV25R: Unraveling of Biological Activities, Selective Anti-Cancer Properties and In Silico Target and Binding Prediction in Hematological Neoplasms

Ladwig, A., Gupta, S. K., Ehlers, P., Sekora, A., Alammar, M., Koczan, D., Wolkenhauer, O., Junghanß, C., Langer, P., & Escobar, H. M. (2023) · Molecules · doi:10.3390/molecules28248120 · Cited by 4

Emerging nanomaterials for cancer immunotherapy

Pandian, S. R. K., Rencilin, C. F., & Sundar, K. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00043 · Cited by 3

Proof of concept: Pull down assay using bovine serum albumin and an immunomodulator small molecule

Tabana, Y., Lin, C. C., Babu, D., Piragasam, R. S., Ponich, A. A., Moon, T. C., Siraki, A. G., Elahi, S., Fahlman, R. P., West, F. G., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21408 · Cited by 2

Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors for Treating Cancer

Sabnis, R. W. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00393 · Cited by 2

pH-responsive polymer-based biomacromolecule nanosponges as biodegradable carriers for DOX deliveryPreprint

Nia, M. H., Ashkar, S., Munguia-López, J. G., Kinsella, J. M., & van de Ven, T. G. M. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-43zr3 · Cited by 2

Imidazoloquinoline optical isomers as TLR7 selective agonists promote macrophage activation for cancer immunotherapy

Pan, Y., Fu, Q., Yang, M., Chen, Z., & Cheng, K. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109041 · Cited by 1

Chemical reprogramming regulates Tip60 expression to improve cleavage rates in somatic cell nuclear transfer reconstituted embryos of cashmere goats

Zhe, X.-S., Zhang, L., Ding, R., Ma, H.-R., Zhang, Y., Hao, F., Liu, D.-J., & Li, Y. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1720533 · Cited by 2

Advanced engineering of hydrogel platforms for cancer immunotherapy via distinct administration routes

Mo, X. W., Min, D. K., & Kim, J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115036 · Cited by 1

Design and Synthesis of Tri-substituted Imidazole Derivatives as CD73 Inhibitors for Their Anticancer Activity

Ghara, A., Andhale, G. S., Matada, G. S. P., & Dhiwar, P. S. (2021) · Letters in Drug Design & Discovery · doi:10.2174/1570180818666210604113849 · Cited by 1

Delivery strategies for ex vivo and in vivo T-cell reprogramming

Ben‐Akiva, E., Karlsson, J. E., Tzeng, S. Y., Yu, H., & Green, J. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00002-6 · Cited by 1

Stimuli-responsive drug delivery systems for cancer immunotherapy

Ding, Y., & Hu, Q. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824456-2.00014-x · Cited by 1

Role of small molecule-based drugs in cancer immunotherapy

Shah, U., Patel, M., Patel, A., Shah, P., Dwivedi, A. R., & Maheshwari, R. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00014-x

Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators

Weinmann, H. (2016) · ChemMedChem · doi:10.1002/cmdc.201500566 · Cited by 122

Small-molecule agents for cancer immunotherapy

Wang, F., Fu, K., Wang, Y., Pan, C., Wang, X., Liu, Z., Yang, C., Zheng, Y. Y., Li, X., Lu, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.010 · Cited by 71

Small-molecule in cancer immunotherapy: Revolutionizing cancer treatment with transformative, game-changing breakthroughs

Chattopadhyay, S., Hazra, R., Mallick, A., Gayen, S., & Roy, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189170 · Cited by 23

Research Advances on Small Molecule Targets for Tumor Immunotherapy

Lie, L., Meng, Y. G., & Shi, J. (2019) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3971/j.issn.1000-8578.2019.19.0094